The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Texas hairstylist Tim Bo Mack opened up to PEOPLE about his years-long struggle to lose weight. He finally found success ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

The GLP-1 conversation is fundamentally a conversation about women’s health access — and we need to start treating it that ...

Use of GLP-1 receptor agonists is associated with a lower risk of death than use of DPP4 inhibitors in older patients with cancer and type 2 diabetes, data suggest.

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the ...